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throughout the sensitivity analyses. CONCLUSIONS: Based on evidence from the
PLATO study, treating a broad spectrum of ACS patients with ticagrelor for one year
seems to offer a cost-effective option in the German health care setting compared
with clopidogrel.
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OBJECTIVES:We examined sponsorship of published economic evaluations of sta-
tin use for cardiovascular (CDV) prevention and evaluated whether funding is as-
sociated with study conclusions.METHODS:A systematic review was conducted in
PubMed/MEDLINE (up to June 2011) to identify cost-effectiveness analyses of statin
use for CDV prevention reporting outcomes as cost per life years gained and/or
quality-adjusted life years. The review was restricted to 6 licensed statins: simva-
statin, pravastatin, fluvastatin, lovastatin, atorvastatin and rosuvastatin. We clas-
sified study intervention data as follows: 1) comparators: statin-statin or statin-
non active drug comparisons, and 2) primary or secondary CDV prevention. We
established relationships between funding source (industry- vs. non-industry-
sponsored studies) and qualitative conclusions (favorable, unfavorable or neutral)
by means tests of differences between proportions. RESULTS: Overall, 72 studies
were included. Thirty-six studies (50%) were carried out in Europe and 31 (43%) in
North America. Fourty-seven (65%) articles compared statins versus non-active
drugs. The category of CDV prevention was distributed as follows: 46% secondary,
39% primary and 15% both. Considering funding source, 64% were industry-spon-
sored studies. For studies evaluating primary CDV prevention, industry-sponsor-
ship was much less likely to have unfavorable or neutral conclusions (0% vs. 59%;
p0.001). Conversely, these differences were not detected for studies evaluating
secondary CDV prevention (0% versus 13%; p0.212). CONCLUSIONS: Our results
suggest that sponsorship of economic evaluation of statins is associated with their
qualitative conclusions in primary CDV prevention.
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OBJECTIVES: The PLATO trial showed that in patients with acute coronary syn-
dromes (ACS) treatment with ticagrelor compared with clopidogrel significantly
reduced the rate of myocardial infarction, stroke, or death from vascular causes
without a significant increase in the rate of overall major bleeding. The aim of this
analysis is to estimate long-term cost-effectiveness of treating ACS patients with
ticagrelor from a Polish health care perspective. METHODS: The model used is a
two-part decision-analytic model, comprising a one-year decision tree and a long-
term Markov model. Model estimates lifetime costs, LYGs and QALYs of treating
ACS patients for one year with ticagrelor plus ASA compared with clopidogrel plus
ASA. The model is based on the results observed in the PLATO study and populated
with the overall clinical, resource use and quality of life results from PLATO trial.
Unit costs were derived from the National Health Fund in Poland. A generic clopi-
dogrel price of 0,92 PLN per day, and a ticagrelor price of 10,85 PLN per day were
applied. Standard mortality rates for the Polish population were used. Data are
presented in PLN with exchange rate: 1,00 PLN € 0,25. RESULTS: Treatment with
ticagrelor was associated with a QALY gain of 0,11 and a LYG gain of 0,12 compared
with clopidogrel. The incremental cost of ticagrelor treatment was 2814 PLN. The
ICER per QALY gained with ticagrelor compared with clopidogrel was 25 675 PLN,
while the ICER per LYG with ticagrelor was 22 257 PLN. Probabilistic sensitivity
analysis indicates that ticagrelor treatment has a 90% probability of being cost
effective given a willingness of pay threshold of 40 000 PLN. The results are consis-
tent in all ACS subgroups. CONCLUSIONS: Based on clinical and health economic
evidence from the PLATO study, treating ACS patients with ticagrelor for one year
is cost-effective compared with clopidogrel in Polish settings.
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OBJECTIVES: Communication impairment after stroke affects everyday activities
and social participation. Speech and Language therapy (SLT) has waiting lists of 6
months plus in the National Health Service (NHS), implying a high opportunity
cost. The aim was to evaluate the cost effectiveness of SLT versus attention control
(AC), at six months, for people with communication difficulties due to aphasia/
dysarthria following stroke. METHODS: The economic analysis was an integral
component of a randomised, controlled, pragmatic trial comparing SLT (n 85) and
AC (n85). The perspective was the NHS and social care, patients and families. The
time horizon was 6 months (baseline to end of scheduled follow up). Resource use
and health status (EQ-5D) were collected on all participants recruited into the trial.
Utility values were estimated from the EQ-5D and associated population tariffs.
The setting was inpatient and community/primary care in North West England;
data were collected between 2006 and 2010. Unit cost data are for 2008-2009. Re-
gression models estimated incremental or costs and outcomes for the ICER, ad-
justed for predefined covariates. Incremental costs and outcomes were boot-
strapped to derive cost effectiveness acceptability curves, net benefit statistics and
probability that SLT was cost effective. RESULTS: The net cost of SLT was £110 (95%
percentiles: -£640 to £861). The net utility was 0.01 (95% percentiles: -0.03 to
0.04). SLT is only likely to be cost effective if decision makers are willing to pay
£25,000 or more to gain a 1 point increase in utility (p0.50). The cost effectiveness
of SLT depends on the outcome measure used and the baseline severity of stroke.
CONCLUSIONS: The primary and sensitivity analyses indicated a high level of
uncertainty suggesting it is not possible to conclude whether therapy is more or
less cost effective than attention control.
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OBJECTIVES: About 33% of patients develop depression after myocardial infarc-
tion, while 25% of patients with diabetes have depression. Patients with co-morbid
depression have lower treatment compliance and health status, increased health-
care use, social isolation and mortality. This study aimed to systematically review
current economic evidence of non-pharmacological treatment interventions for
patients with CHD or diabetes and co-morbid clinically-relevant depression.
METHODS: The electronic search strategies (conducted in MEDLINE, EMBASE, Psy-
cINFO, CINAHL, NHS EED) combined clinical search terms with terms used by the
UK National Health Service Economic Evaluation Database (NHSEED), to identify
full economic evaluations of the relevant interventions. Pre-specified screening
and inclusion criteria were used. Standardised data extraction and critical ap-
praisal (using NHSEED criteria) were conducted. RESULTS: Excluding duplicates,
1336 studies for CHD and 1281 for diabetes were screened. Four economic evalua-
tions were identified (two for diabetes and two for CHD). The studies found that the
interventions improved health status, reduced depression and were cost-effective
compared to usual care. Both CHD studies were UK-based and used home-based
cognitive behavioural programmes. The net costs were -£42 to £2, the net QALY
gains were 0.006 to 0.009. The diabetes studies were based on US-based and used
stepped collaborative care programmes delivered by specialised nurses. The net
costs were -$1378 to $216, the net gains in depression free days were 53 to 115.
CONCLUSIONS: The review highlighted the paucity of evidence in this area and
associated uncertainty. Four small studies indicated the potential of psychological
interventions to improve the quality of life, reduce depression and be cost-effective
compared to usual care. Robust and well-designed economic evaluations of non-
pharmacological treatment interventions for patients with co-morbid depression
are needed. An economic model is being developed to synthesise data from various
sources to explore this further.
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OBJECTIVES: To estimate the cost-effectiveness of closing the statin ‘treatment
gap’ in the secondary prevention of coronary artery disease (CAD) in Australia.
METHODS:We developed a decision-analysis Markov model with yearly cycles and
the following health states: ‘Alive’ and ‘Dead’. Using data from the Australian
Reduction of Atherothrombosis for Continued Health (REACH) registry, the model
compared current statin coverage (82%) in the secondary prevention of CAD (‘Cur-
rent’ group) with a hypothetical situation of 100% coverage (‘Improved’ group). The
18% gap was filled with use of generic statins. Data from a recent meta-analysis
were used to estimate the benefits of statin use in terms of reducing recurrent
cardiovascular events and death. Government-reimbursement data from 2011 was
used to calculate direct healthcare costs. The cost of the intervention to improve
statin coverage was assumed to be $250 per person. Years of life lived and costs
were discounted at 5% annually. RESULTS: Among the 2058 subjects in the ‘Cur-
rent’ group, the model estimated that there would be 106 non-fatal myocardial
infractions, 68 non-fatal strokes and 275 deaths over five years. In the ‘Improved’
group, within which all subjects took statins, the corresponding numbers were 101,
65, and 259, equating to numbers needed to treat of 426, 639, and 127, respectively.
Over the five years, there would be 0.018 life years gained (discounted) at a net cost
of AUD $546 (discounted) per person. These equated to an incremental cost-effec-
tiveness ratio (ICER) of AUD $29,717 per life year gained. CONCLUSIONS: The re-
sults suggest that for patients with CAD, maximizing coverage with statins, in line
with evidence-based recommendations, represents a cost-effective means of sec-
ondary prevention.
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OBJECTIVES: To evaluate the cost-effectiveness of one-year treatment with clopi-
dogrel plus aspirin compared to aspirin alone in patients without ST-segment el-
evation (NSTEMI) from the Greek third-party-payer perspective. METHODS: A
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Markov model for evaluating the long-term cost-effectiveness of clopidogrel in
patients with NSTEMI was adapted and extended by using local utility and eco-
nomic values. The effect of clopidogrel was applied during the first year in the
model and was estimated by the CURE trial. Costs assigned to each health state
included antiplatelet treatment cost, cost for the management of adverse events
and the costs for concomitant medication, hospitalization, outpatient visits, reha-
bilitation and nursing. The incremental cost-effectiveness ratio (ICER) was calcu-
lated. A probabilistic sensitivity analysis was conducted in order to assess the
impact of all uncertain model parameters varying simultaneously. The results are
presented as mean (95% Uncertainty Interval (UI)). RESULTS: The analysis showed
a discounted survival of 8.27 (8.25-8.30) years in the aspirin treatment group and
8.42 (8.39-8.44) years in the aspirinclopidogrel treatment group; a difference of
0.14 (0.11-0.18, p0.001) years. Adjusting the survival for the quality of life, the
model predicts 7.52 (7.15–7.79) and 7.66 (7.27–7.94) discounted QALYs in the aspirin
and clopidogrelaspirin arm, respectively, resulting in a difference of 0.14 QALYs
(0.10-0.17, p0.001). The cumulative lifetime costs per patient were € 15,976
(€14,848–€17.156) and € 15,392 (€14,301- €16,535), for aspirin and
clopidogrelaspirin treatment arm, respectively, a difference of € 584 (€525-€647).
The ICER was €4111 (€3342–€5169) for each life-year saved and €4385 (€3487–€5647)
for each QALY saved. For a decision threshold of €5500 per discounted QALY,
clopidogrelaspirin is cost-effective in more than 95% of randomly sampled
analyses. CONCLUSIONS: Treatment with clopidogrel in addition to aspirin is a
cost-effective treatment option in patients with NSTEMI from the perspective of a
third-party payer in Greece.
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OBJECTIVES: To estimate the cost-effectiveness of Dabigatran etexilate 150dib rel-
ative to Sintrom, Aspirin, Aspitin-Clopidogrel, Best Supportive Care and no treat-
ment, in the management of patients with Atrial Fibrillation in the Greek health
care setting. METHODS: A Markov model was adopted to estimate long term out-
comes of patients moving during their lifetime in between the following health
states: primary and recurrent ischemic stroke, hemorrhagic stroke, transient isch-
emic attack, systemic embolism, acute myocardial infarction, intracranial hemor-
rhage, extracranial hemorrhage and death. Data on event rates and patent quality
of life associated with different health states and patient survival times were based
on a multinational clinical trial (RE-LY) and the related literature. Furthermore,
data on resource use associated with the management of patients and of different
events were collected from a survey of local hospitals. Unit prices were collected
from official resources and relate to 2011. A 3.5% discount rate was used for all
outcomes. Sensitivity analysis and probabilistic analysis was used to test the ro-
bustness of the analysis RESULTS: The mean total life-time cost of patients on
Dabigatran etexilate was estimated at €20,103, relative to €11,639 in the case of
Sintrom, while mean Quality Adjusted Life Years (QALYs) were 9.86 and 9.83 for the
two treatments, respectively. The incremental cost-effectiveness ratio of Dabiga-
tran etexilate relative to Sintrom was estimated at €25,952. Similarly it was esti-
mated at €8,223, €10,392 and €7,536 against Asprin-Clopidogrel, Aspirin alone and
No-Tretament, respectively. Sensitivity analyses indicated that the cost-effective-
ness of Dabigatran etexilate remained below acceptable thresholds (€50,000 per
QALY gained) in significant variations of baseline parameters. Probabilistic analy-
sis indicated that in about 85% of cases its cost-effectiveness ratios, relative to the
above comparators were below the aforementioned threshold. CONCLUSIONS:
Dabigatran etexilate may represent a cost-effective choice for the management of
patients with atrial fibrillation in Greece.
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OBJECTIVES: To conduct an economic analysis comparing treatment with clopi-
dogrel against aspirin in patients with peripheral artery disease, a recent stroke, or
a recent myocardial infarction from the Greek third-party-payer perspective.
METHODS: A Markov model with a 6-month cycle length was developed to evalu-
ate the lifetime cost-effectiveness of clopidogrel versus aspirin. The effect of clopi-
dogrel was applied only during the first 2 years of the model and this was retrieved
from CAPRIE trial. Local utility data were used to estimate quality-adjusted life
years (QALY). The state-specific costs consists of the costs that reflect and encap-
sulate all resource used for the care of patients within the health care system
during a 6-month period in the acute and follow-up phase, separately. The cost-
effectiveness of clopidogrel over aspirin was evaluated by calculating the incre-
mental cost per life year saved (LYS) and incremental cost per QALY saved (ICER). A
probabilistic sensitivity analysis was conducted and the results are presented as
mean (95% Uncertainty Interval (UI)). RESULTS: The analysis showed that the dis-
counted survival was 11.83 (11.41-12.22) years and 12.17 (11.75-12.55) years in as-
pirin and clopidogrel treatment group, respectively, a difference of 0.27 (0.10-0.45)
life-years. The corresponding discounted QALYs were 8.63 (8.34 – 8.91) and 8.84
(8.54–9.10), respectively. The cumulative lifetime costs per patient were €19,880
(€18,863–€20,939) and €21,039 (€20,006–€22,089), for aspirin and clopidogrel treat-
ment arm, respectively. The ICER was calculated to be € 4,921 (€ 3,079–€ 9,969) for
each LYS and €6,326 (€ 3,737–€ 16,699) for each QALY saved. For a “willigness-to-
pay” threshold of € 9,500 per discounted QALY, clopidogrel was found to be cost-
effective in more than 90% of randomly sampled analyses. CONCLUSIONS: This
economic analysis indicates that treatment with clopidogrel for secondary preven-
tion of cardiovascular events in atherothrombotic patients is a cost-effective anti-
platelet treatment over aspirin in a Greek third-party payer perspective.
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OBJECTIVES: To evaluate common therapeutic alternatives (rosuvastatin, atorvas-
tatin, simvastatin, pravastatin) for the prevention of primary and secondary car-
diovascular events in Greece. METHODS: A Markov model with distinct health
states (no event, fatal/non fatal acute myocardial infarction (MI), fatal/non fatal
stroke, post-MI, post-stroke & all cause death) was developed, to reflect within a
20-year time span health and economic outcomes of non-smoking patients as-
sumed to be at base line at mean age of 70 years, with no prior treatment of
hypertension, systolic blood pressure at 140mmHg and total cholesterol at 260mg/
Dl. The HellenicSCORE risk score equation was used to transform systolic blood
pressure reductions in different medications into long-term reductions in cardio-
vascular events. Transition probabilities from acute myocardial infarction or
stroke to death were obtained from the Framingham study. Treatment cost was
estimated from a payer perspective and includes the cost of medication and all
resources used in the management of events. Health states were associated with
local quality of life data to estimate Quality Adjusted Life Years (QALYs). A proba-
bilistic sensitivity analysis was conducted to deal with uncertainty. Prices reflect
2011 and outcomes were discounted at 3.5%. RESULTS: For males, discounted
QALYs were: 10.18 (95%CI:10.11-10.23), 10.04 (95%CI:9.96-10.10), 9.94 (95%CI: 9.84-
10.02) and 9.88 (95%CI: 9.76-9.97) for rosuvastatin, atorvastatin, simvastatin and
pravastatin, respectively. The mean total cost was: 15,646 (95%CI:15,173-16,130),
16,678 (95%CI:16,184-17,187), 17,242 (95%CI:16,732-17,766) and 17,585 (95%CI:
17,060-18,119) respectively. For females, QALYs were: 10.33 (95%CI:10.28-10.37),
10.26 (95%CI:10.20-10.30), 10.20 (95%CI:10.13-10.25) and 10.16 (95%CI: 10.08-10.22),
respectively. Similarly, mean total cost was: 15,030 (95%CI:14,632-15,430), 15,608
(95%CI:15,192-16,023), 15,951 (95%CI:15,521-16,379) and 16,153 (95%CI:15,714-
16,591) respectively. Hence rosuvastatin was a dominant therapy option.
CONCLUSIONS: Rosuvastatin may represent an attractive option relative to alter-
native therapies, from an economic and clinical point of view, in the primary and
secondary prevention of cardiovascular events in the National Health Service of
Greece.
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OBJECTIVES: The cost-effectiveness study of pravastatin for primary prevention of
coronary artery disease (CAD) was assessed applying epidemiologic data and risk
predictions of CAD in Japan. METHODS: A Markov transition model was used for
evaluating the cost-effectiveness of 20mg/day of pravastatin treatment with diet
therapy. The incidence of acute myocardial infarction (AMI) was estimated using
newly developed risk predictions of CAD in Japan. Hypothetical population of men
and women from 45 to 75 years old were assumed according to the cardiac risk
factors from Japan Atherosclerosis Society Guideline for Prevention of Atheroscle-
rotic Cardiovascular Disease. Quality-adjusted life-years (QALYs) and incremental
cost-effectiveness ratios (ICERs) over a lifetime horizon were estimated from the
perspective of payers. One way sensitivity analysis and probabilistic sensitivity
analysis were conducted to see the robustness of the model. RESULTS: The pre-
dicted incidence of AMI was 4.4/10,000 person-years for men and 1.4/10,000 per-
son-years for women aged 55 years with initial total cholesterol level (TC) of 240
mg/dl without other cardiac risk factors (i.e. low cardiac risk) and 20.1/10,000 per-
son-years for men and 6.6/10,000 person-years for women with initial TC level of
240 mg/dl, and risks of smoking, hypertension and diabetes (i.e. high cardiac risk).
Over a lifetime horizon, the ICERs were depended on the level of cardiac risk fac-
tors. The ICERs were decreased proportionally with increased age and number of
cardiac risk factors. Considering the willingness to pay threshold per QALYs, prav-
astatin treatment was not cost-effective in all subgroups evaluated in this study.
CONCLUSIONS: Due to the predicted low incidence of CAD in Japan, pravastatin
treatment was not cost-effective for primary prevention of CAD in population not
only at low cardiac risk but also at high cardiac risk. Further evaluations of cost-
effectiveness on CAD treatment in Japan using available epidemiological data and
risk predictions are needed.
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